This article is more than 5 years old. Information may no longer be current.
EyePoint reports lower net loss for second quarter
EyePoint Pharmaceuticals reported a second quarter net loss of $11.5 million, or $0.11 per share, compared with a net loss of $34.4 million, or $0.62 per share, in the same quarter of 2018, according to a press release.
Total quarterly revenue was $7.2 million, with net product revenue of $6.7 million generated from sales of Yutiq (fluocinolone acetonide intravitreal implant).
Research and development expenses were approximately $4 million in the second quarter of 2019 compared with $4.8 million a year ago, and general and administrative costs increased from $4.2 million to $4.8 million. Sales and marketing expenses increased from $1.5 million in 2018 to $7.2 million in 2019.
EyePoint had cash and cash equivalents of $44.2 million as of June 30.